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1082-187 Elevated Fibrinogen Level and Risk of Future Incidence 
of Diabetes Mellitus: Bezafibrate Infarction Prevention 
(BIP) Study
Moti Haim, Michal Benderly, Valentina Boyko, Alexander Tenenbaum, Uri Goldbourt, 
Alexander Battler, Solomon Behar, Rabin Medical Center, Petah-Tikva, Israel, Neufeld 
Cardiac Research Institute, Tel-Hashomer, Israel
Background: In healthy people increased levels of inflammatory mediators predict the
development of DM.
Aim: To assess the association between plasma fibrinogen and subsequent incidence of
diabetes mellitus
Methods: Among 3122 patients included in BIP study 546 who had DM in baseline were
excluded. We measured baseline plasma fibrinogen levels before allocation to bezafi-
brate or placebo. Incident diabetes mellitus was defined as fasting plasma glucose above
126 mg/dl or commencement of insulin or oral hypo-glycemics. Mean Follow-up time was
6 years.
Results: Among the 2576 Without DM at baseline, 546 (21%) developed DM during fol-
low-up, and 2030 (79%) did not. Baseline characteristics are shown in the table. The age
adjusted relative risk of incident DM (as compared to the 1st tertile concentration of
fibrinogen) was 1.39 (95% CI, 1.02-1.89) in the second tertile and 1.54 (95% CI , 1.14-
2.09)in the third. After adjustment for confounders associated with the incidence of DM
and with fibrinogen (including: age, body mass index, baseline fasting plasma glucose,
HDL-C, triglycerides, hypertension, smoking, and use of thiazide diuretics and bezafi-
brate) the corresponding relative risk of incident DM were :1.32 (95% CI, 0.97-1.81), and
1.39 (95% CI, 1.02-1.90).
Conclusions: Elevated fibrinogen levels were associated with increased future risk of
developing DM.
1082-188 Carotid Artery Intima-Media Thickness Progression 
Rates in Young Adults: The Bogalusa Heart Study
James H. Stein, Pamela S. Douglas, Maureen E. Mays, Sathanur R. Srinivasan, Wei 
Chen, Gerald S. Berenson, University of Wisconsin, Madison, WI, Tulane University, New 
Orleans, LA
Background
Carotid intima-media thickness (CIMT) measurements are used to assess the effects of
pharmacological interventions on atherosclerotic burden and to evaluate cardiovascular
risk. Although aging-related CIMT changes for middle-aged and older adults have been
published, these values have not been described in a large population of young adults.
CIMT measurements from the Bogalusa Heart Study, a longitudinal study of the natural
history of atherosclerosis in young adults and children, were used to characterize age-,
race-, and sex-specific CIMT progression rates.
Methods 
High-resolution B-mode ultrasound images of the far walls of the common, bulb, and
internal carotid artery segments were measured. Cross-sectional rates of mean CIMT
change were estimated using ordinary least-squares regression and compared using
Z-transformation procedure, with adjustments for height and weight.
Results 
CIMT was measured in 519 young adults aged 20-38 years old (mean 32 years, 61%
female, 29% black). Composite CIMT progression rates (table) did not differ significantly
across sex-race strata. As in middle-aged and older adults, carotid atherosclerosis
increases more rapidly in the bulb.
Conclusions
CIMT increases with aging, even in young adults. These CIMT progression rates can be
used to plan clinical trials of anti-atherosclerotic therapies in young adults and can be
used as reference values for young adults being monitored for atherosclerosis progres-
sion.
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1083-189 Modulating Effects of Cholesterol Elevation by Diet-
Feeding and Cholesterol Lowering by Simvastatin on 
Platelet-Activating Factor Acetylhydrolase Activity, 
Paraoxonase Activity, and Lysophosphatidylcholine 
Concentration
Bo Zhang, Eiso Shimoji, Ping Fan, Keijiro Saku, Fukuoka University, Fukuoka, Japan
Background: Platelet-activating factor acetylhydrolyse (PAF-AH), a lipoprotein-associ-
ated phospholipase A2, degrades PAF and bioactive oxidized lipids to produce lyso-PAF
and lysophosphatidylcholine (lyso-PC). However, plasma PAF-AH activity has been
reported to be a risk factor for coronary heart disease (CHD) and its levels is increased in
patients with familial hypercholesterolemia. Therefore, it would be interesting to deter-
mine how cholesterol levels modulate plasma PAF-AH activity. Paraosonase (Pon1) is an
enzyme that is exclusively associated with HDL and shows PAF-AH-like activity. We
examined the effects of cholesterol elevation by cholesterol feeding and cholesterol-low-
ering by simvastatin on plasma, HDL- and LDL-associated PAF-AH activity, plasma lyso-
PC conc., and serum Pon1 activity .
Methods: Japanese White rabbits (n=22) were fed a diet containing 0.3% cholesterol
and 3% corn oil for one month (Part I), and then divided into 2 groups that continued to
receive this diet with (treated) or without (control) treatment with simvastatin (0.01%) for
another 2 months (Part II). PAF-AH activity, lyso-PC concentration, Pon1 activity, and
serum levels of lipids and lipoproteins were measured during Part I and Part II.
Results: Cholesterol feeding significantly increased serum levels of TC, phospholipids,
HDL-C, and LDL-C, plasma and HDL- and LDL-associated PAF-AH activities, and
plasma lyso-PC concentration, the ratio of HDL-PAF-AH to LDL-PAF-AH, and decreased
Pon1 activity. Simvastatin treatment partly reversed these effects, indicating that choles-
terol levels affect PAF-AH activity, and its distribution between lipoproteins, and the enzy-
matic composition of HDL. However, the ratio of PAF-AH to TC was markedly decreased
by cholesterol feeding, and increased by simvastatin treatment, indicating that plasma
PAF-AF activity did not change proportionally with TC levels and also that the effect of
simvastatin on PAF-AH activity was not completely dependent on its cholesterol-lowering
effect.
Conclusion: Cholesterol levels significantly modulate PAF-AH activity, indicating that
cholesterol levels should be considered when evaluating the relevance of PAF-AH in
CHD.
1083-190 Pitavastatin, a Potent Hydroxymethylglutaryl Coenzyme 
A Reductase Inhibitor, Increases Cholesterol 7a-
hydroxylase Gene Expression in HepG2 Cells
Ping Fan, Bo Zhang, Eiso Shimoji, Keijiro Saku, Fukuoka University, Fukuoka, Japan
Background: Pitavastatin, a newly developed super-statin, produces potent LDL-C-low-
ering effect in patients with familial hypercholesterolemia. Since bile acid depletion sub-
stantially reduces cholesterol levels in Watanabe heritable hyperlipidemic rabbits, in
which LDL receptor does not function, it would be interesting to determine whether or not
pitavastatin affects bile acid synthesis and, if so, to determine a possible molecular mech-
anism. We examined the effects of pitavastatin on the mRNA levels of cholesterol 7- α
hydroxylase (CYP7A1), the rate-limiting enzyme in the bile acid synthesis pathway, farne-
soid X receptor (FXR), peroxisome proliferator activated receptor α (PPAR α), and apoli-
poprotein (apo) A-I in HepG2 cells.
Methods: HepG2 cells were cultured in serum-free DMEM for 18 h before drug treat-
ment. Total RNA was extracted at indicated time and mRNA levels were quantified by RT-
real time PCR.
Results: Pitavastatin dose-dependently increased mRNA levels of apo A-I, PPARα,
CYP7A1, and FXR at 24 h. Mevalonate reversed the effects of pitavastatin on the expres-
sion of these genes. While apo A-I and PPARα mRNA levels were time-dependently
increased by pitavastatin, the CYP7A1 mRNA level first decreased at 6 and 12 h and
* p<0.05,
DM+ DM-
Age (yrs, SD) 60 (6.6) 60 (6.8)
Body Mass Index (kg/m2, SD) 27.9 (3.6) 26.3 (3.0)*
Glucose (mg/dl, SD) 106 (12) 94 (10)*
HDL-C (mg/dl, SD) 33.5 (5.4) 34.8 (5.5)*
Triglycerides (mg/dl, SD) 157(53) 142 (50)*
Men (%) 91 92
HTN (%) 31 30
Fibrinogen (mg/dl, SD) 361 (73) 347 (72)*
CIMT Progression Rates (mm/year, 95% confidence intervals)
White 
Males
(N=142)
Black 
Males
(N=63)
White 
Females
(N=227)
Black 
Females(N=87)
Common 
Carotid
0.0094
(0.0043 - 0.0145)
-0.0001
(-0.0069 - 0.0067)
0.0055
(0.0022 - 0.0088)
0.0062
(-0.0003 - 0.0128)
Bulb 0.0204
(0.0075 - 0.0334)
0.0145
(-0.0024 - 0.0314)
0.0113
(0.0053 - 0.0173)
0.0119
(-0.0008 - 0.0246)
Internal Carotid 0.0045
(-0.0041 - 0.0131)
0.0067
(-0.0037 - 0.0171)
-0.0015
(-0.0081 -0.0050)
0.0055
(-0.0035 - 0.0146)
Composite 0.0116
(0.0040 - 0.0191)
0.0060
(-0.0047 - 0.0166)
0.0045
(0.0003 - 0.0087)
0.0081
(0.0009 - 0.0154)
